Pemigatinib for previously treated locally advanced/metastatic cholangiocarcinoma (CCA): Update of FIGHT-202.

Ghassan K. Abou-Alfa,Vaibhav Sahai,Antoine Hollebecque,Gina M. Vaccaro,Davide Melisi,Raed Al-Rajabi,Andrew Scott Paulson,Mitesh J. Borad,David Gallinson,Adrian Murphy,Do-Youn Oh,Efrat Dotan,Daniel V.T. Catenacci,Eric Van Cutsem,Christine F. Lihou,Hui-Ling Zhen,Luis Féliz,Arndt Vogel

Pemigatinib for previously treated locally advanced/metastatic cholangiocarcinoma (CCA): Update of FIGHT-202.

2021

Ghassan K. Abou-Alfa
Vaibhav Sahai
Antoine Hollebecque
Gina M. Vaccaro
Davide Melisi
Raed Al-Rajabi
Andrew Scott Paulson
Mitesh J. Borad
David Gallinson
Adrian Murphy
Do-Youn Oh
Efrat Dotan
Daniel V.T. Catenacci
Eric Van Cutsem
Christine F. Lihou
Hui-Ling Zhen
Luis Féliz
Arndt Vogel

4086Background: Pemigatinib (PEMI), a potent, selective, oral FGFR1-3 inhibitor, has shown efficacy and safety in patients (pts) with CCA and FGFR2 rearrangements/fusions in FIGHT-202 (NCT02924376;...

Keywords:

locally advanced
Medicine
Internal medicine
Oncology
in patient
previously treated

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations